Imunon, Inc. will hold a conference call on May 12, 2026, to report its first quarter financial results and update investors on the clinical development of IMNN-001, its DNA-based immunotherapy for advanced ovarian cancer. The company is advancing Phase 3 trials of IMNN-001, which aims to boost cancer-fighting molecules at tumor sites. This update follows successful Phase 2 trials showing improved survival rates, positioning IMNN-001 as a promising treatment option. Investors can join the call via phone or webcast to learn more about the company’s progress and future plans.
A leading semiconductor exchange-traded fund (ETF) has delivered an impressive average annual return of 14% since 2001. Over the last twelve months alone, the ETF surged by 118%, highlighting strong growth in the chip sector. This performance undersc...
Bonterra Energy is transitioning from dry gas production to focus on the more profitable liquids-rich Charlie Lake interval in Canada. This shift is expected to improve paybacks and internal rates of return (IRRs), especially given current strong liq...
Jefferies reviewed valuations of five precious metals miners in Europe, Middle East, and Africa, highlighting Endeavour Mining as having the most upside potential. They rate Endeavour as a 'buy' due to its attractive valuation at 4.4 times next year'...
Atlantic.Net, a global cloud services provider, has been named the top HIPAA-compliant cloud storage provider for 2026 by DesignRush. The company is recognized for its secure, managed cloud platform tailored to healthcare organizations, featuring enc...
The Hyperliquid Policy Center and trade[XYZ] have petitioned the CFTC to adopt a unified regulatory framework that treats energy perpetual contracts the same as crypto perpetual contracts, focusing on their economic structure rather than the underlyi...
